Q4 2024 Earnings Call Transcript March 20, 2025 ARS Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.52, ...

Good day, and welcome to ARS Pharmaceuticals fourth quarter and full year 2024 financial results conference call. (Operator Instructions) As a reminder, this call is being recorded. I would now like ...

Multiple favorable coverage decisions secured, including by Express Scripts, Cigna Healthcare, OptumRx ... to Medicaid coverage with no prior authorization in Texas, Alabama and Montana, with ...

The massive pharmacy benefit manager plans to stop requiring coverage reauthorizations for roughly 80 drugs used to treat ...

The PBM plans to stop requiring coverage reauthorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and ...

Optum Rx, the pharmacy benefit manager under UnitedHealth Group, is set to eliminate prior authorization requirements for ...

Optum Rx announced on Wednesday that it will eliminate up to 25% of reauthorizations, initially focusing on 80 drugs. | Optum ...

Optum Rx has eliminated reauthorization for almost 70 drugs for chronic diseases, about 10% of its overall pharmacy prior ...

Optum Rx is shifting its payment models to better meet the needs of pharmacies and consumers, the pharmacy benefit manager ...

The massive PBM is pivoting to a cost-based reimbursement model, which it says will reduce variation in how pharmacies are ...

Initiative will eliminate up to 25% of all reauthorizations, or 10% of overall prior authorizations, PBM says.